Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Other Accumulated Expenses (2021 - 2025)

Historic Other Accumulated Expenses for Universe Pharmaceuticals (UPC) over the last 5 years, with Q3 2025 value amounting to -$706.1 million.

  • Universe Pharmaceuticals' Other Accumulated Expenses fell 10005.57% to -$706.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$706.1 million, marking a year-over-year decrease of 10005.57%. This contributed to the annual value of -$706.1 million for FY2025, which is 10005.57% down from last year.
  • As of Q3 2025, Universe Pharmaceuticals' Other Accumulated Expenses stood at -$706.1 million, which was down 10005.57% from $1266.9 billion recorded in Q3 2024.
  • Over the past 5 years, Universe Pharmaceuticals' Other Accumulated Expenses peaked at $1266.9 billion during Q3 2024, and registered a low of -$706.1 million during Q3 2025.
  • Over the past 5 years, Universe Pharmaceuticals' median Other Accumulated Expenses value was $444319.0 (recorded in 2021), while the average stood at $253.3 billion.
  • In the last 5 years, Universe Pharmaceuticals' Other Accumulated Expenses soared by 171269371.6% in 2024 and then plummeted by 10005.57% in 2025.
  • Quarter analysis of 5 years shows Universe Pharmaceuticals' Other Accumulated Expenses stood at $444319.0 in 2021, then plummeted by 88.24% to $52263.0 in 2022, then surged by 141426.51% to $74.0 million in 2023, then surged by 1712693.72% to $1266.9 billion in 2024, then plummeted by 100.06% to -$706.1 million in 2025.
  • Its last three reported values are -$706.1 million in Q3 2025, $1266.9 billion for Q3 2024, and $74.0 million during Q3 2023.